Material and Methods: Data was collected from July 2014-September 2015. 341 (of 673) entries associated with plan rejection were categorized as changes in one of the following:
(1) tumor anatomy/patient setup;
(2) dose/volume; (3) tumor/OAR constraints; (4) treatment planning modification generated during plan review; and (5) external (patient-, disease-, or hospital/equipmentgenerated) causes. Each entry was initiated by the physician, physicist, or dosimetrist involved in planning. Analyzed time intervals included the following: (1) dosimetry contours; (2) MD contour approval; (3) dosimetry plan computed; (4) physics plan precheck; (5) MD plan approval; and (6) total time for planning from simulation/planning board entry until MD plan approval (TMD). The data was analyzed with Twoway ANOVA, Student T-test, and Pearson correlation.
Results:
The mean TMD time was 85 hrs (+/-45). With breakdown by interval, the mean dosimetry contour (16 hrs), MD contour approval (27 hrs), dosimetry planning (12 hrs), physics precheck (4 hrs), and MD approval (11 hrs) times were calculated. The planning modification category was a significant source of variation in planning time (p<0.0001). Treatment planning modifications presented the predominant (50%) source of planning delay, followed by constraint (26%), dose/volume (18%), external (4%), and tumor anatomy/patient setup changes (2%). Those with tumor anatomy/patient setup or dose/volume changes resulted in the longest TMD, dosimetry contour, dosimetry plan computing, and MD plan approval intervals. 27% of plan modifications were initiated by physicians, 70% by physicists, and 3% by dosimetrists. Entries initiated by physicians on the planning board were associated with shorter TMD times than when physicists initiated plan rejection (p=0.016).
Conclusion:
We report a novel process for quantification of clinical RT plan rejections. In this analysis, tumor anatomy/patient setup or dose/volume changes resulted in the longest treatment TMD times. Physician-initiated plan modification entries were associated with shorter TMD times, which may denote early, proactive involvement-an optimal approach with complicated or aggressive disease. Though planning delays may depend on department infrastructure and patient population, our method provides a comprehensive census to optimize planning throughput and can be applied as a part of broader process improvement.
PO-0860
Is there a "best technique" available for reducing acute toxicities in craniospinal Irradiation? M. Devecka Purpose or Objective: Craniospinal irradiation is performed rarely in a palliative intention due to concerns of acute toxicities (mostly dysphaghia and bone marrow supression). Therefore the purpose of this study was to evaluate the dosimetric parameters responsible for the acute toxicity in patients with leptomeningeal metastasis of a solid cancer treated with craniospinal irradiation (CSI) by helical tomotherapy (HT), 3D conformal radiotherapy (3D-CRT) and Protons.
Material and Methods: Data of five adult patients previously treated with HT CSI were evaluated. For each patient the initial tomotherapy plan (inHT) was compared to a 3D conformal plan (3D-CRT), a scanning proton beam plan (p-CSI) as well as to a specifically optimized bone marrow (BM) sparing tomotherapy plan (BM-HT). The BM-HT was also optimized to reduce the acute dysphagia. The prescribed dose was 36 Gy. All active bone marrow compartments were delineated separately according to Campbell et al. To analyse the impact of different bone marrow compartments weighted bone marrow exposure (WBME) was used. WBME Dmean = Σ(proportion (%) of functional bone marrow according to anatomical site x Dmean to anatomical site) WBME V20 = Σ(proportion (%) of functional bone marrow according to anatomical site x V20 to anatomical site) This calculation was also performed for V30. Further, the following organ at risks (OARs) were delineated: left and right submandibular glands, the parotid glands, the eyes, the cochlea, the oral cavity, the pharynx, the thyroid gland, the esophagus, the heart, both lungs, both kidneys, the liver, the bowel, and the pancreas. For all of these structures the Dmean in all four treatment plans were analyzed.
Descriptive statistics were used to analyze the results.
Results: p-CSI results in the best sparing of the organs at risk (OARs) including the active bone marrow compartments. BM-HT achieved better results as inHT and 3D-CRT regarding bone marrow sparing (see Figure 1. ). Dose to the crucial OARs responsible for dysphagia was also reduced with BM-HT. The trade off for this was an slightly increased lung and kidney dose. Figure 1 . Total bone marrow and weighted bone marrow dosimetry (presented are averages and 95% confidence intervals).
________________________________________________________________________________

Conclusion:
With the use of the novel techniques such as p-CSI and BM-HT quality of life impairing acute side effects such as cytopenias and dysphagia can be reduced. We propose WBME to better assess the impact on active bone marrow. Conventionally this treatment has been delivered with standard AP-PA fields. To minimise cardiac radiation dose and reduce the risk of subsequent late complications, we validated the use of VMAT to deliver WLI without increasing the predicted risks of secondary breast cancers compared to AP-PA fields.
PO-0861
Material and Methods:
Five female patient datasets (ages ranging from 3 to 18 years) were used for this retrospective study. The planning target volume (PTV) included total lung volume with a 1 cm margin (and adjacent vertebrae for three patients). Organs at risks included were heart, breast bud/tissue, liver and thyroid. 6 MV AP-PA (with segments) and RapidArc (2 or 3 full arcs) plans were created using the Eclipse treatment planning system (Version 11). Plans were calculated using the anisotropic analytical algorithm (AAA). The prescribed dose was either 15 Gy in 10 fractions or 18 Gy in 12 fractions based on the patient's age. PTV D2%, D98% and D50% and mean and maximum doses for heart and breast were obtained. The absolute excess risk (AER) of cardiac mortality at 15 years post treatment was calculated for each plan based on an age-at-exposure adjusted relative risk per Gy obtained from published data (1,2,3,4) combined with contemporary UK population-based absolute risks. The risk of breast cancer induction was calculated using the model proposed by Schneider et al. (2011) (5) .
Results:
The VMAT plans resulted in a similar minimum PTV coverage when compared to the AP-PA plans whilst reducing the PTV D2% by an average of 6.1% (4.1 -9.1). The use of VMAT reduced the heart and breast mean dose by an average of 19.1% (11.7 -30.5) and 16.2% (-2.2 -30.4) respectively when compared to the AP-PA plans. The difference in AER of cardiac mortality at 15 years was lower for the VMAT plans by an average of 0.48% (0.11 -0.98). The average excess absolute risk (EAR) for breast cancer induction across all plans decreased by 2.9% (-0.8 -6.8 ) when compared to the conformal plans (assuming α/β = 3 Gy, α = 0.067 Gy-1, R = 0.62, µ = 4.8/10000PY/Gy).
Conclusion:
VMAT achieved highly conformal plans and reduced cardiac late normal tissue complication probability whilst also reducing (or achieving similar) predicted risk of second cancer induction in breast tissue. Purpose or Objective: Traditionally, patients with rectal cancer (T2 anterior low rectum, T3-T4 N0-N+) are treated with preoperative radiotherapy or chemoradiation (CAP 50 regimen). 3D Conformal Radiation Therapy is conventionally delivered: 44 Gy more 6 Gy as a sequential boost to the high risk target volume (total dose 50 Gy). Another strategy would be to use the Contact Therapy technique [1] using 50 kV Xrays (CXRT) to deliver higher dose (30 Gy) to the high risk target volume in addition to 44 Gy. The present study first describes CXRT dose computation with Monte-Carlo simulations and then compares the resulting dose (EBRT+CXRT) with the conventional treatment (EBRT only).
PO-0862
Material and Methods:
The CXRT machine Papillon 50™ installed in Centre Antoine Lacassagne (Nice, France) delivers a 50 kV X-ray beam with a dose rate close to 15 Gy/min, allowing treatment delivery more comfortable for the patients [2]. The system is currently used for treating skin and rectal cancers. The detailed geometry of the Papillon 50™ machine [3] was fully generated in Monte-Carlo code PenEasy based on PENELOPE [4] and the resulting simulations were validated against measurements in water (depth dose curves and transverse dose profiles) for all applicators used for rectum cancer. For 10 patients with T2-T3 nodes smaller than 3 cm, dose distributions were calculated to irradiate the high risk target volume. For each patient, 30 Gy CXRT dose was computed with Monte-Carlo simulation in 3DCT patient data acquired in a position close to the rectal cancer CXRT position (genupectoral position). 6 Gy EBRT treatment was computed with the commercial TPS Isogray (Dosisoft) in the 3DCT scan acquired in supine position. Both dose distributions were compared in terms of dosimetric indices computed for target volumes (conformity and homogeneity indices) and dose to organs at risk.
Results:
Monte-Carlo penEasy simulations are in good agreement with the Papillon50TM measurements in water for
